- Home
- SYBX vs PULM Comparison
SYBX vs PULM Comparison
Compare SYBX & PULM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SYBX
- PULM
- Stock Information
- Founded
- SYBX N/A
- PULM 2003
- Country
- SYBX United States
- PULM United States
- Employees
- SYBX N/A
- PULM N/A
- Industry
- SYBX Biotechnology: Pharmaceutical Preparations
- PULM Biotechnology: Pharmaceutical Preparations
- Sector
- SYBX Health Care
- PULM Health Care
- Exchange
- SYBX Nasdaq
- PULM Nasdaq
- Market Cap
- SYBX 16.4M
- PULM 18.3M
- IPO Year
- SYBX N/A
- PULM N/A
- Fundamental
- Price
- SYBX $1.71
- PULM $4.89
- Analyst Decision
- SYBX
- PULM
- Analyst Count
- SYBX 0
- PULM 0
- Target Price
- SYBX N/A
- PULM N/A
- AVG Volume (30 Days)
- SYBX 21.1K
- PULM 9.6K
- Earning Date
- SYBX 11-11-2025
- PULM 11-07-2025
- Dividend Yield
- SYBX N/A
- PULM N/A
- EPS Growth
- SYBX N/A
- PULM N/A
- EPS
- SYBX N/A
- PULM N/A
- Revenue
- SYBX N/A
- PULM $369,000.00
- Revenue This Year
- SYBX N/A
- PULM N/A
- Revenue Next Year
- SYBX N/A
- PULM $134.88
- P/E Ratio
- SYBX N/A
- PULM N/A
- Revenue Growth
- SYBX N/A
- PULM N/A
- 52 Week Low
- SYBX $0.90
- PULM $1.96
- 52 Week High
- SYBX $1.96
- PULM $10.40
- Technical
- Relative Strength Index (RSI)
- SYBX 69.98
- PULM 45.65
- Support Level
- SYBX $1.45
- PULM $4.70
- Resistance Level
- SYBX $1.77
- PULM $5.19
- Average True Range (ATR)
- SYBX 0.07
- PULM 0.15
- MACD
- SYBX 0.03
- PULM 0.07
- Stochastic Oscillator
- SYBX 83.33
- PULM 44.44
About SYBX Synlogic Inc.
Synlogic Inc is a biopharmaceutical company focuses on rare metabolic disorders, with a lead program in phenylketonuria (PKU) and homocystinuria (HCU). The company's pipeline includes therapeutics for enteric hyperoxaluria, gout, and cystinuria. Using a proprietary approach, the company engineer GI-restricted, oral medicines from well-characterized probiotics. These drug candidates target specific biological pathways, leveraging Escherichia coli Nissle 1917 for consistency and safety. Engineered to be non-colonizing and reversible, the company offer oral administration, simplifying shipping and storage. The company operates in one segment-discovery and development of Synthetic Biotics-pioneering transformative treatments for serious diseases.
About PULM Pulmatrix Inc.
Pulmatrix Inc is a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented dry powder delivery technology, iSPERSE. Its pipeline of clinical assets includes PUR3100 for the treatment of acute migraine, PUR1800 for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD), and PUR1900 for the treatment of ABPA in patients with asthma and in patients with cystic fibrosis (CF).